Drug-Disease Severity and Target-Disease Severity Interaction Networks in COVID-19 Patients.

Pharmaceutics · 2022 · PMC9504398 · PMID 36145576

Europe PMC DOI

hedged sentences

0.0010

closest p · 0.0× alpha

0.0600

boldest claim

The sentences

highly significantp < 0.001actually significant

Molecular targets with highly significant ( p < 0.001) differences are given in the Supplements, Figure S2 .

also in 132,142 other papers

borderline significantp = 0.06so close (0.05 < p ≤ 0.1)

However, anti-hyperglycemics , specifically dipeptidyl peptidase-4 (DPP4) inhibitors and sodium glucose co-transporter 2 (SGLT2) inhibitors (only borderline significant, p = 0.06), were taken more often by non-severe COVID-19 patients with cardiovascular conditions or cardiovascular conditions and diabetes (see Supplements, Table S3 ).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.